Plain-English translation of NCT06139224 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a prebiotic supplement—a special fiber that feeds healthy bacteria in your gut—in people living with HIV who are on effective antiretroviral therapy. Researchers believe that both HIV and alcohol use can damage the gut barrier and increase harmful inflammation in the body, even when HIV is well-controlled by medications. The medication may help restore gut health and reduce this inflammation.
People living with HIV often experience high levels of inflammation and related health problems, even when their HIV is well-controlled by treatment. Early research suggests that damage to the gut and loss of healthy bacteria may be driving this inflammation, especially in people who also struggle with alcohol use. This trial aims to test whether healing the gut with this treatment could reduce inflammation and improve overall health.
You likely qualify if…
You likely don't qualify if…
You will participate in this study for 8 weeks total. You'll visit the clinic in person 3 times and have 4 virtual check-ins. The study uses a crossover design, meaning you'll take the prebiotic supplement for 4 weeks, then switch to placebo (inactive pill) for 4 weeks—or vice versa, depending on which group you're randomly assigned to. This way, your own body serves as a comparison, helping researchers see how the medication actually affects you.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
United States